Targeted radiation drug takes aim at bone metastases in early trial

NCT ID NCT07087197

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called SKB107 in people with advanced solid tumors that have spread to the bones. The drug delivers a small amount of radiation directly to bone tumors. The study will enroll about 90 adults to check if the drug is safe, how it moves through the body, and whether it can slow bone tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB107 (a radioactive drug that targets bone)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancer that has spread to the bones.
What could go wrong: This is a very early Phase 1 trial with only 90 participants, so the main goal is safety, not effectiveness. The drug is radioactive, which carries risks like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR WITH BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic carcinoma in the bone metastatic malignant neoplasm metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMORS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.